« Back to Record
Citation APA

Bregni, G., Vandeputte, C., Pretta, A., Senti, C., Trevisi, E., Acedo Reina, E., Kehagias, P., Liberale, G., Moretti, L., Bali, M. A., Demetter, P., Flamen, P., Carrasco, J., D'Hondt, L., Geboes, K., Gokburun, Y., Peeters, M., Van Den Eynde, M., Van Laethem, J.-L., Vergauwe, P., Chapot, C. A., Buyse, M., Deleporte, A., Hendlisz, A., & Sclafani, F. (2021). Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer. Acta oncologica. doi:10.1080/0284186X.2020.1871067


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/319728

Bregni, G., Vandeputte, C., Pretta, A., Senti, C., Trevisi, E., Acedo Reina, E., Kehagias, P., Liberale, G., Moretti, L., Bali, M. A., Demetter, P., Flamen, P., Carrasco, J., D'Hondt, L., Geboes, K., Gokburun, Y., Peeters, M., Van Den Eynde, M., Van Laethem, J.-L., Vergauwe, P., Chapot, C. A., Buyse, M., Deleporte, A., Hendlisz, A., & Sclafani, F. (2021). Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer. Acta oncologica. doi:10.1080/0284186X.2020.1871067